keyword
MENU ▼
Read by QxMD icon Read
search

Cardio-oncology

keyword
https://www.readbyqxmd.com/read/28911261/out-of-the-frying-pan-and-into-the-fire-damage-associated-molecular-patterns-and-cardiovascular-toxicity-following-cancer-therapy
#1
Nicole S Klee, Cameron G McCarthy, Patricia Martinez-Quinones, R Clinton Webb
Cardio-oncology is a new and rapidly expanding field that merges cancer and cardiovascular disease. Cardiovascular disease is an omnipresent side effect of cancer therapy; in fact, it is the second leading cause of death in cancer survivors after recurrent cancer. It has been well documented that many cancer chemotherapeutic agents cause cardiovascular toxicity. Nonetheless, the underlying cause of cancer therapy-induced cardiovascular toxicity is largely unknown. In this review, we discuss the potential role of damage-associated molecular patterns (DAMPs) as an underlying contributor to cancer therapy-induced cardiovascular toxicity...
September 1, 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/28862931/cardiovascular-adverse-events-in-patients-with-cancer-treated-with-bevacizumab-a-meta-analysis-of-more-than-20%C3%A2-000-patients
#2
REVIEW
Matthias Totzeck, Raluca Ileana Mincu, Tienush Rassaf
BACKGROUND: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life-threatening cardiovascular adverse effects could limit its use and may warrant specific follow-up strategies. METHODS AND RESULTS: We systematically searched MEDLINE, Cochrane, EMBASE, and Web of Science for randomized controlled trials published until November 2016 that assessed patients with cancer treated with or without bevacizumab in addition to standard chemotherapy...
August 10, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28862319/breakthroughs-in-modern-cancer-therapy-and-elusive-cardiotoxicity-critical-research-practice-gaps-challenges-and-insights
#3
REVIEW
Ping-Pin Zheng, Jin Li, Johan M Kros
To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune-based therapeutic modalities of anticancer treatment (the fifth modality), e...
September 1, 2017: Medicinal Research Reviews
https://www.readbyqxmd.com/read/28824714/cardiac-metabolic-deregulation-induced-by-the-tyrosine-kinase-receptor-inhibitor-sunitinib-is-rescued-by-endothelin-receptor-antagonism
#4
Joevin Sourdon, Franck Lager, Thomas Viel, Daniel Balvay, Rebecca Moorhouse, Evangeline Bennana, Gilles Renault, Pierre-Louis Tharaux, Neeraj Dhaun, Bertrand Tavitian
The growing field of cardio-oncology addresses the side effects of cancer treatment on the cardiovascular system. Here, we explored the cardiotoxicity of the antiangiogenic therapy, sunitinib, in the mouse heart from a diagnostic and therapeutic perspective. We showed that sunitinib induces an anaerobic switch of cellular metabolism within the myocardium which is associated with the development of myocardial fibrosis and reduced left ventricular ejection fraction as demonstrated by echocardiography. The capacity of positron emission tomography with [(18)F]fluorodeoxyglucose to detect the changes in cardiac metabolism caused by sunitinib was dependent on fasting status and duration of treatment...
2017: Theranostics
https://www.readbyqxmd.com/read/28822531/cardio-oncology-a-new-subspecialty-with-collaboration-at-its-heart
#5
REVIEW
Arjun K Ghosh, J Malcolm Walker
Cardio-Oncology is the care of cancer patients with cardiovascular disease, overt or occult, already established or acquired during treatment. Cancer patients can present with a variety of cardiovascular problems not all of which are directly related to cancer therapy (medications or radiotherapy). The cardiovascular problems of oncology patients can range from ischaemia to arrhythmias and can also include valve problems and heart failure. As such, within cardiology, teamwork is required with members of different cardiology subspecialties...
July 2017: Indian Heart Journal
https://www.readbyqxmd.com/read/28785479/cancer-and-heart-failure-understanding-the-intersection
#6
Carine E Hamo, Michelle W Bloom
Cancer and cardiovascular disease account for nearly half of all deaths in the US. The majority of cancer therapies are known to cause potential cardiac toxicity in some form. Patients with underlying cardiac disease are at a particularly increased risk for worse outcomes following cancer therapy. Most alarming is the potential for heart failure as a result of cancer treatment, which may lead to early disruption or withdrawal of life-saving cancer therapies and can potentially increase cardiovascular mortality...
April 2017: Card Fail Rev
https://www.readbyqxmd.com/read/28781723/developing-a-comprehensive-cardio-oncology-program-at-a-cancer-institute-the-moffitt-cancer-center-experience
#7
REVIEW
Michael G Fradley, Allen C Brown, Bernadette Shields, Federico Viganego, Rongras Damrongwatanasuk, Aarti A Patel, Gregory Hartlage, Natalee Roper, Julie Jaunese, Larry Roy, Roohi Ismail-Khan
Cardio-oncology is a multidisciplinary field focusing on the management and prevention of cardiovascular complications in cancer patients and survivors. While the initial focus of this specialty was on heart failure associated with anthracycline use, novel anticancer agents are increasingly utilized and are associated with many other cardiotoxicities including hypertension, arrhythmias and vascular disease. Since its inception, the field has developed at a rapid pace with the establishment of programs at many major academic institutions and community practices...
June 14, 2017: Oncology Reviews
https://www.readbyqxmd.com/read/28759384/cardiotoxic-effects-of-anthracycline-based-therapy-what-is-the-evidence-and-what-are-the-potential-harms
#8
REVIEW
Bennett E Levis, Phillip F Binkley, Charles L Shapiro
Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-based guidelines exist for the surveillance and prevention of chemotherapy-induced cardiotoxicity in adult survivors of breast cancer who have had limited previous doses of anthracyclines (ie, total cumulative dose 240 mg/m(2)), or limited-dose anthracyclines followed by trastuzumab-based regimens. Nonetheless, some national and international cardio-oncology and cardiac-imaging organisations recommend increased cardiac surveillance during or after treatment, measurement of cardiac biomarkers and other surrogate endpoints, and in some cases initiation of cardioprotective drug therapy in asymptomatic women...
August 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28751851/anmco-aiom-aico-consensus-document-on-clinical-and-management-pathways-of-cardio-oncology-executive-summary
#9
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, Nicola Maurea, Maurizio Giuseppe Abrignani, Irma Bisceglia, Daniella Bovelli, Luisa De Gennaro, Donatella Del Sindaco, Francesca Macera, Iris Parrini, Donatella Radini, Giulia Russo, Angela Beatrice Scardovi, Alessandro Inno
Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28713868/21st-century-cardio-oncology-identifying-cardiac-safety-signals-in-the-era-of-personalized-medicine
#10
Calvin Chen Sheng, Laleh Amiri-Kordestani, Todd Palmby, Thomas Force, Charles C Hong, Joseph C Wu, Kevin Croce, Geoffrey Kim, Javid Moslehi
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than traditional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies...
August 2016: JACC. Basic to Translational Science
https://www.readbyqxmd.com/read/28707189/cardio-oncology-gaps-in-knowledge-goals-advances-and-educational-efforts
#11
REVIEW
Gina Biasillo, Carlo M Cipolla, Daniela Cardinale
Over the past 20 years, cancer treatments have become more effective, leading to significant improvements in survival rates. However, anticancer drugs can have several possible cardiovascular side effects; in particular, the development of left ventricular dysfunction with chemoradiation therapy can negatively affect patients' cardiac outcome, and can limit anticancer treatments. This is an ongoing issue that will continue to persist, due to the ongoing development of new antitumor agents with potential cardiotoxic effects, and the prolonged life expectancy of long-term cancer survivors...
August 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28683963/the-horizon-in-cardio-oncology-you-are-only-as-good-as-your-endothelium
#12
EDITORIAL
Daniel J Lenihan
No abstract text is available yet for this article.
July 11, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28680277/trastuzumab-induced-cardiotoxicity-testing-a-clinical-risk-score-in-a-real-world-cardio-oncology-population
#13
M Rushton, C Johnson, S Dent
BACKGROUND: Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important consideration for clinicians and patients. We reviewed the current literature on predicting trastuzumab-related cardiotoxicity and tested a clinical risk score (crs) in a real-world breast cancer population to assess its utility in predicting permanent cardiotoxicity...
June 2017: Current Oncology
https://www.readbyqxmd.com/read/28679288/chemotherapy-induced-cardiotoxicity-in-children
#14
REVIEW
Neha Bansal, Shahnawaz Amdani, Emma R Lipshultz, Steven E Lipshultz
With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity...
August 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28674089/grounding-cardio-oncology-in-basic-and-clinical-science
#15
Javid Moslehi, Dulguun Amgalan, Richard N Kitsis
No abstract text is available yet for this article.
July 4, 2017: Circulation
https://www.readbyqxmd.com/read/28664530/cme-instructions-comprehensive-review-on-cardio-oncology-role-of-multimodality-imaging
#16
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
https://www.readbyqxmd.com/read/28660778/cardio-oncology-cardiovascular-complications-of-cancer-therapy
#17
Robert J Henning, Raymond D Harbison
This paper focuses on three classes of commonly used anticancer drugs, which can cause cardiotoxicity: anthracyclines, monoclonal antibodies exemplified by trastuzumab and tyrosine kinase inhibitors. Anthracyclines can induce cardiomyocyte necrosis and fibrosis. Trastuzumab can cause cardiac stunning. The tyrosine kinase inhibitors can increase systemic arterial pressure and impair myocyte contractility. In addition, radiation therapy to the mediastinum or left chest can exacerbate the cardiotoxicity of these anticancer drugs and can also cause accelerated atherosclerosis, myocardial infarction, heart failure and arrhythmias...
July 2017: Future Cardiology
https://www.readbyqxmd.com/read/28649481/cardio-oncology-cancer-therapy-related-cardiovascular-complications-in-a-molecular-targeted-era-new-concepts-and-perspectives
#18
REVIEW
David Hurtado-de-Mendoza, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes, Gabriel Tinoco, Rodrigo Alcorta
Cardio-oncology is a medical discipline that identifies, prevents, and treats the cardiovascular complications related to cancer therapy. Due to the remarkable proliferation of new cancer therapies causing cardiovascular complications, such as hypertension, heart failure, vascular complications, and cardiac arrhythmia, we provide an extensive, comprehensive revision of the most up-to-date scientific information available on the cardiovascular complications associated with the use of newer, novel chemotherapeutic agents, including their reported incidence, suggested pathophysiology, clinical manifestations, potential treatment, and prevention...
May 18, 2017: Curēus
https://www.readbyqxmd.com/read/28639454/the-role-of-cardiac-mri-in-cardio-oncology
#19
Juan Lopez-Mattei, Cezar Iliescu, Jean Bernard Durand, Saamir Hassan, Peter Kim, Lilia Sierra-Galan, Greg Gladish
No abstract text is available yet for this article.
July 2017: Future Cardiology
https://www.readbyqxmd.com/read/28631773/-cardiovascular-complications-of-cancer-chemotherapy-the-need-for-cardio-oncology
#20
Alberto Dolara
Traditional chemotherapic agents as antraciclines and radiumtherapy are known to be the cause of cardiovascular complications from many years. Nevertheless also recent drugs, which were initially considered effective only on cancer cells are now recognized to exert negative effects also on the cardiovascular system. The frequency and the entity of the effects are variable for each drug and depend from the clinical status of the patient. It is therefore necessary the creation of a team of oncologists and cardiologists for the prevention and therapy of cardiovascular complications...
June 2017: Recenti Progressi in Medicina
keyword
keyword
50
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"